14.38
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché KROS Giù?
Forum
Previsione
Precedente Chiudi:
$14.43
Aprire:
$14.39
Volume 24 ore:
287.73K
Relative Volume:
0.44
Capitalizzazione di mercato:
$584.05M
Reddito:
-
Utile/perdita netta:
$-168.05M
Rapporto P/E:
-2.8031
EPS:
-5.13
Flusso di cassa netto:
$-146.15M
1 W Prestazione:
+0.14%
1M Prestazione:
+4.89%
6M Prestazione:
+21.45%
1 anno Prestazione:
-70.99%
Keros Therapeutics Inc Stock (KROS) Company Profile
Nome
Keros Therapeutics Inc
Settore
Industria
Telefono
617-314-6297
Indirizzo
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Confronta KROS con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
KROS
Keros Therapeutics Inc
|
14.38 | 586.08M | 0 | -168.05M | -146.15M | -5.13 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-06-10 | Downgrade | BofA Securities | Buy → Neutral |
2025-01-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
2025-01-17 | Downgrade | Wedbush | Outperform → Neutral |
2024-12-16 | Downgrade | Guggenheim | Buy → Neutral |
2024-12-16 | Reiterato | Oppenheimer | Outperform |
2024-12-13 | Reiterato | H.C. Wainwright | Buy |
2024-12-12 | Downgrade | BTIG Research | Buy → Neutral |
2024-12-12 | Downgrade | TD Cowen | Buy → Hold |
2024-12-12 | Downgrade | William Blair | Outperform → Mkt Perform |
2024-11-05 | Iniziato | Jefferies | Buy |
2024-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
2024-09-23 | Iniziato | Guggenheim | Buy |
2024-06-25 | Iniziato | Oppenheimer | Outperform |
2024-02-21 | Iniziato | William Blair | Outperform |
2023-12-08 | Iniziato | Wells Fargo | Overweight |
2023-07-31 | Iniziato | Wedbush | Outperform |
2023-07-26 | Iniziato | BofA Securities | Buy |
2023-02-14 | Iniziato | Cowen | Outperform |
2022-10-18 | Iniziato | Truist | Buy |
2022-07-26 | Iniziato | BTIG Research | Buy |
2020-12-08 | Reiterato | H.C. Wainwright | Buy |
2020-05-04 | Iniziato | H.C. Wainwright | Buy |
2020-05-04 | Iniziato | Jefferies | Buy |
2020-05-04 | Iniziato | Piper Sandler | Overweight |
2020-05-04 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Keros Therapeutics Inc Borsa (KROS) Ultime notizie
How high can Keros Therapeutics Inc. stock price go in 2025Consistent high-performance stocks - jammulinksnews.com
Is Keros Therapeutics Inc. a good long term investmentExplosive wealth accumulation - jammulinksnews.com
What drives Keros Therapeutics Inc. stock priceHigh-profit trading signals - jammulinksnews.com
What analysts say about Keros Therapeutics Inc. stockFast-track wealth growth - jammulinksnews.com
Keros Therapeutics Inc. Stock Analysis and ForecastTriple-digit profit margins - jammulinksnews.com
(KROS) Trading Signals - news.stocktradersdaily.com
Should I buy Keros Therapeutics Inc. stock before earningsHigh Confidence Trade Setups - Newser
Keros Therapeutics Begins Phase 3 Trial for Elritercept - TipRanks
Keros Therapeutics doses first patient in Phase 3 MDS trial By Investing.com - Investing.com South Africa
Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept - The Manila Times
Keros Therapeutics doses first patient in Phase 3 MDS trial - Investing.com
Why Keros Therapeutics Inc. stock attracts strong analyst attentionLow Drawdown Trade Signals - Newser
How Keros Therapeutics Inc. stock performs during market volatilityFree Signals Group - Newser
What makes Keros Therapeutics Inc. stock price move sharplyFree Trading Strategy Suggestions - Newser
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives $30.56 Average Target Price from Brokerages - MarketBeat
Trend Tracker for (KROS) - news.stocktradersdaily.com
Sarcopenia Market Expected to Experience Major Growth by 2034, According to DelveInsight | TNF Pharma, Lipocine, Biophytis, ImmunoForge, Rejuvenate Biomed, Keros Therapeutics, BPGbio, Oncocross - Barchart.com
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Keros Therapeutics, Inc.(NasdaqGM: KROS) dropped from Russell 3000 Growth Index - MarketScreener
Keros Therapeutics, Inc.(NasdaqGM: KROS) added to Russell 2000 Value Index - MarketScreener
(KROS) Trading Report - news.stocktradersdaily.com
Keros Therapeutics, Inc. (KROS) Halts PAH Drug Development After Safety Concerns in TROPOS Trial - MSN
Layoff Tracker: Gilead Cuts 36 Employees in California - BioSpace
Analysts Set Keros Therapeutics, Inc. (NASDAQ:KROS) Target Price at $30.56 - MarketBeat
Bank of America Downgrades Keros Therapeutics (NASDAQ:KROS) to Neutral - MarketBeat
Two Sigma Investments LP Buys 23,342 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Shares Gap DownTime to Sell? - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Downgraded to Neutral Rating by Bank of America - Defense World
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst - Benzinga
Keros Therapeutics Inc Azioni (KROS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):